article · Infection and Drug Resistance
Antimicrobial resistance poses a substantial danger to global health, with Methicillin-resistant Staphylococcus aureus (MRSA) representing a major public health concern. In certain regions, up to 90% of S. aureus infections are MRSA, which cannot be managed using standard antibiotics and increases the risk of mortality by 64% relative to drug-sensitive strains. Resistance to methicillin is primarily caused by the expression of penicillin-binding protein 2a, which prevents beta-lactam antibiotics from functioning, alongside the generation of beta-lactamases. Because conventional treatments are increasingly restricted, alternative therapeutic solutions are required. These non-antibiotic strategies include bacteriophages, immunotherapy, nanobiotics, and antimicrobial peptides, which offer broad activity and synergistic effects. A combined approach using both established interventions and novel tools is essential to address the spread of resistant strains across community and healthcare environments.
Drug-resistant bacterial infections are increasingly difficult to manage using standard medications, leading to higher death rates in hospitals and communities. Understanding the mechanisms that protect bacteria from antibiotics helps guide the creation of non-traditional therapies, ensuring healthcare providers have workable tools to treat severe infections when typical drugs fail.
The identified alternative therapies, such as nanobiotics, antimicrobial peptides, immunotherapy, and bacteriophages, could enable novel therapeutics for clinical healthcare providers treating resistant bacterial infections. Based on the abstract, these strategies appear to be at an early research and conceptual stage requiring further exploration, though the text provides no specific details on direct development pathways or timeframes to market.
AI-generated from the published abstract. Always read the original work before citing.
Abstract: Antimicrobial resistance (AMR) represents a major threat to global health. Infection caused by Methicillin-resistant Staphylococcus aureus (MRSA) is one of the well-recognized global public health problem globally. In some regions, as many as 90% of S. aureus infections are reported to be MRSA, which cannot be treated with standard antibiotics. WHO reports indicated that MRSA is circulating in every province worldwide, significantly increasing the risk of death by 64% compared to drug-sensitive forms of the infection which is attributed to its antibiotic resistance. The emergence and spread of antibiotic-resistant MRSA strains have contributed to its increased prevalence in both healthcare and community settings. The resistance of S. aureus to methicillin is due to expression of penicillin-binding protein 2a (PBP2a), which renders it impervious to the action of β-lactam antibiotics including methicillin. The other is through the production of beta-lactamases. Although the treatment options for MRSA are limited, there are promising alternatives to antibiotics to combat the infections. Innovative therapeutic strategies with wide range of activity and modes of action are yet to be explored. The review highlights the global challenges posed by MRSA, elucidates the mechanisms underlying its resistance development, and explores mitigation strategies. Furthermore, it focuses on alternative therapies such as bacteriophages, immunotherapy, nanobiotics, and antimicrobial peptides, emphasizing their synergistic effects and efficacy against MRSA. By examining these alternative approaches, this review provides insights into the potential strategies for tackling MRSA infections and combatting the escalating threat of AMR. Ultimately, a multifaceted approach encompassing both conventional and novel interventions is imperative to mitigate the impact of MRSA and ensure a sustainable future for global healthcare. Keywords: MRSA, AMR, resistome, phage therapy, nanoparticles, antimicrobial peptides, lytic
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.2147/idr.s428103
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.
